Yahoo
Stockholm - Delayed Quote SEK

Xbrane Biopharma AB (publ) (XBRANE.ST)

14.15 +1.15 (+8.85%)
At close: October 30 at 12:59:30 PM GMT+1
XBRANE.ST Q3 2026 earnings call
Replay the call for the latest insights.
View in AlphaSpace Currency in SEK All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
83,342
152,400
148,100
238,800
57,700
Cost of Revenue
77,387
62,808
18,225
203,341
0
Gross Profit
5,910
89,546
129,873
35,388
57,618
Operating Expense
113,520
157,702
249,183
345,344
231,186
Operating Income
-107,610
-68,156
-119,310
-309,956
-173,568
Net Non Operating Interest Income Expense
-6,203
-15,685
-32,498
137
-2,295
Pretax Income
-73,906
-43,933
-129,723
-322,028
-168,513
Tax Provision
96
2,234
11,589
0
0
Net Income Common Stockholders
-74,997
127,242
-266,220
-388,172
-172,513
Diluted NI Available to Com Stockholders
-74,997
127,242
-266,220
-388,172
-172,513
Basic EPS
-16.11
0.08
-27.50
-82.50
-0.77
Diluted EPS
-16.11
0.08
-27.50
-82.50
-0.77
Basic Average Shares
20,604.34
16,430.42
9,839.30
4,736.92
225,550.68
Diluted Average Shares
20,604.34
16,434.84
9,840.17
4,736.92
225,550.68
Total Operating Income as Reported
-67,703
-28,248
97,224
-322,164
-166,217
Total Expenses
190,907
220,510
267,408
548,685
231,186
Net Income from Continuing & Discontinued Operation
-74,997
127,242
-266,220
-388,172
-172,513
Normalized Income
-106,589.94
-78,755.94
-158,097.95
-322,028
-168,512
Interest Income
--
711
501
2,407
296
Interest Expense
2,556
12,038
30,617
18,501
2,583
Net Interest Income
-6,203
-15,685
-32,498
137
-2,295
EBIT
-71,350
-31,895
-99,106
-303,527
-165,930
EBITDA
-71,350
-10,752
-63,153
-269,791
-165,930
Reconciled Cost of Revenue
77,387
62,808
18,225
203,341
0
Reconciled Depreciation
--
21,143
35,953
33,736
--
Net Income from Continuing Operation Net Minority Interest
-74,001
-46,167
-141,312
-322,028
-168,512
Total Unusual Items Excluding Goodwill
41,044
41,044
21,141
0
0
Total Unusual Items
41,044
41,044
21,141
0
0
Normalized EBITDA
-112,394
-51,796
-84,294
-269,791
-165,930
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
8,455.06
8,455.06
4,355.05
0
0
12/31/2022 - 2/3/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: